FDA delays its decision on earlier Abecma treatment for RRMM
The U.S. Food and Drug Administration (FDA) is delaying its review of an application that seeks to allow the cell therapy Abecma (idecabtagene vicleucel) to…
Marisa Wexler, MS, senior science writer — 
Articles by Marisa Wexler
Elrexfio for RRMM recommended in EU for conditional approval
A committee of the European Medicines Agency (EMA) has recommended that Elrexfio (elranatamab) — a therapy already in use in the U.S. — be…
Effect of diabetes on survival in myeloma may differ by race: Study
While diabetes is more frequent among Black people than white people, it’s associated with poorer survival outcomes in white people with multiple myeloma, a…
Phase 3 trial of Venclexta for hard-to-treat myeloma misses main goal
People with hard-to-treat multiple myeloma given a regimen of Venclexta (venetoclax) plus dexamethasone lived longer than those treated with Pomalyst (pomalidomide) plus the…
1st human trial to test LBL-034 for hard-to-treat myeloma in US, China
Nanjing Leads Biolabs is planning to launch a first-in-human clinical trial to test LBL-034, an antibody-based therapy designed to trigger the immune system to…
Myeloma cells in lab, mice killed with nanoparticle-delivered RNA
Researchers at Tel Aviv University in Israel have developed a new nanoparticle system that can deliver RNA-based therapies designed to kill myeloma cells in…
FDA puts CART-ddBCMA Phase 2 trial on hold after patient’s death
The U.S. Food and Drug Administration (FDA) has placed a hold on clinical testing of CART-ddBCMA, a cell therapy that Arcellx and Kite…
Carvykti outperforms standard care as earlier line of therapy: Analysis
Carvykti (ciltacabtagene autoleucel) significantly reduces the risk of disease progression or death in adults with multiple myeloma who received one to three prior lines…
Sarclisa plus Kyprolis found to stop cancer for nearly 3 years in trial
Sarclisa (isatuximab), given on top of standard treatment with Kyprolis (carfilzomib) and the steroid dexamethasone, was found to delay disease progression by almost…
Dramatic gains in survival seen in myeloma since early 2000s: Analysis
Survival outcomes for people with multiple myeloma have improved substantially over the last two decades, likely due to the availability of new, more effective…